Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
AXSM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$64.11 - $139.13
Previous CloseN/A
Volume140.83K
Average Volume (3M)825.15K
Market Cap
$5.52B
Enterprise Value$5.61B
Total Cash (Recent Filing)$331.44M
Total Debt (Recent Filing)$189.43M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 11, 2025EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding49,219,310
10 Day Avg. Volume661,231
30 Day Avg. Volume825,150
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.08
Forecast
1Y Price Target
$173.38Price Target Upside56.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAxsome announced positive results from the EMERGE Phase 3 trial of SYMBRAVO, showing significant improvement in migraine treatment compared to previous inhibitors.
Financial OutlookThe company believes its current cash reserves should fund operations until reaching cash flow-positive status, potentially early next year.
Market DemandAxsome's lead product, AUVELITY, saw a significant increase in prescriptions, indicating strong market demand and growth potential.
Bears Say
Earnings PerformanceAXSM reported an EPS of -$1.22 versus consensus of -$0.98 mainly driven by higher SG&A.
Financial PerformanceAxsome reported financial results that moderately missed forecasts, with top-line revenue and net loss figures not meeting expectations.
Operating ExpensesOperating expenses were higher than anticipated, especially in sales and marketing, which may affect future financial performance.
---
Ownership Overview
1.41% Insiders
19.89% Mutual Funds
1.64% Other Institutional Investors
63.94% Public Companies and
Individual Investors
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $64.11 and its highest was $139.13 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $5.52B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Aug 11, 2025 which is in 94 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on May 05, 2025. The company reported -$1.22 earnings per share for the quarter, beating the consensus estimate of -$1.351 by $0.131.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -1.06.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 49,219,310 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$1.22 in its last earnings report, beating expectations of -$1.351. Following the earnings report the stock price went up 3.814%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in AXSM
---
Axsome Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$173.38 (56.40% Upside)
$173.38 (56.40% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.69%
12-Months-Change
Fundamentals
Return on Equity
-282.16%
Trailing 12-Months
Asset Growth
9.33%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
---
AXSM Company Deck
---
AXSM Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong revenue growth, successful product launches, and significant pipeline advancements. However, the company faces challenges in achieving profitability and navigating regulatory and market landscapes.Read More>---
AXSM Stock 12 Month Forecast
Average Price Target
$173.38
▲(56.40% Upside)
Technical Analysis
Cytokinetics
―
Sarepta Therapeutics
―
Blueprint Medicines
―
Verona Pharma
―
Krystal Biotech
―
---